Table 1.
Baseline patient data for training and validation groups.
| Variable | Level | Training group (N = 40,527) | Validation group (N = 801) | P |
|---|---|---|---|---|
| Marital (%) | Married | 25,058 (61.83) | 509 (63.55) | 0.3406 |
| Unmarried | 15,469 (38.17) | 292 (36.45) | ||
| Age (median [IQR]) | NA | 64.000 [55.000, 73.000] | 64.000 [55.000, 73.000] | 0.5425 |
| Tumor.Size (median [IQR]) | NA | 41.000 [26.000, 67.000] | 40.000 [26.000, 70.000] | 0.7579 |
| Race.ethnicity (%) | Black | 5,068 (12.51) | 0 (0.00) | <0.0001 |
| Chinese | 493 (1.22) | 801 (100.00) | ||
| Other | 3,197 (7.89) | 0 (0.00) | ||
| White | 31,769 (78.39) | 0 (0.00) | ||
| Sex (%) | Female | 14,278 (35.23) | 290 (36.20) | 0.5934 |
| Male | 26,249 (64.77) | 511 (63.80) | ||
| Sequence.number (%) | More | 13,360 (32.97) | 245 (30.59) | 0.1673 |
| One primary only | 27,167 (67.03) | 556 (69.41) | ||
| Time [mean (SD)] | NA | 39.125 (30.668) | 37.527 (30.902) | 0.1443 |
| Status (%) | Alive | 29,880 (73.73) | 583 (72.78) | 0.5749 |
| Dead | 10,647 (26.27) | 218 (27.22) | ||
| Primary.Site (%) | C64.9-Kidney | 38,525 (95.06) | 718 (89.64) | <0.0001 |
| C65.9-Renal pelvis | 2,002 (4.94) | 83 (10.36) | ||
| Grade (%) | Moderately differentiated | 13,895 (34.29) | 296 (36.95) | <0.0001 |
| Poorly differentiated | 8,519 (21.02) | 239 (29.84) | ||
| Undifferentiated; anaplastic | 3,210 (7.92) | 63 (7.87) | ||
| Unknown | 11,708 (28.89) | 127 (15.86) | ||
| Well differentiated | 3,195 (7.88) | 76 (9.49) | ||
| Laterality (%) | Left | 20,044 (49.46) | 391 (48.81) | 0.0231 |
| Other | 77 (0.19) | 5 (0.62) | ||
| Right | 20,406 (50.35) | 405 (50.56) | ||
| Pathological (%) | 8,312/3: Renal cell carcinoma | 7,381 (18.21) | 136 (16.98) | 0.0079 |
| 8,120/3: Transitional cell carcinoma, NOS | 1,088 (2.68) | 33 (4.12) | ||
| 8,130/3: Papillary transitional cell carcinoma | 995 (2.46) | 26 (3.25) | ||
| 8,260/3: Papillary adenocarcinoma, NOS | 5,028 (12.41) | 76 (9.49) | ||
| 8,310/3: Clear cell adenocarcinoma | 21,479 (53.00) | 442 (55.18) | ||
| 8,317/3: Renal cell carcinoma, chromophobe type | 2,136 (5.27) | 49 (6.12) | ||
| Other(n < 1,000) | 2,420 (5.97) | 39 (4.87) | ||
| T (%) | T1 | 26,430 (65.22) | 481 (60.05) | 0.0238 |
| T2 | 4,036 (9.96) | 100 (12.48) | ||
| T3 | 8,075 (19.92) | 174 (21.72) | ||
| T4 | 1,101 (2.72) | 23 (2.87) | ||
| TX | 885 (2.18) | 23 (2.87) | ||
| N (%) | N0 | 36,472 (89.99) | 707 (88.26) | 0.0142 |
| N1 | 2,349 (5.80) | 64 (7.99) | ||
| N2 | 195 (0.48) | 0 (0.00) | ||
| NX | 1,511 (3.73) | 30 (3.75) | ||
| M (%) | M0 | 35,653 (87.97) | 678 (84.64) | 0.005 |
| M1 | 4,874 (12.03) | 123 (15.36) | ||
| Surgery (%) | Any nephrectomy in continuity with the resectiont | 308 (0.76) | 7 (0.87) | 0.0034 |
| Complete/total/simple nephrectomy | 3,601 (8.89) | 80 (9.99) | ||
| Local tumor destruction | 2,000 (4.93) | 51 (6.37) | ||
| Local tumor excision | 852 (2.10) | 30 (3.75) | ||
| No surgery of primary site | 7,371 (18.19) | 156 (19.48) | ||
| Partial/subtotal nephrectomy/partial ureterectomy | 11,472 (28.31) | 198 (24.72) | ||
| Radical nephrectomy | 14,923 (36.82) | 279 (34.83) | ||
| Radiation (%) | None/Unknown | 38,930 (96.06) | 770 (96.13) | 0.9922 |
| Yes | 1,597 (3.94) | 31 (3.87) | ||
| Chemotherapy (%) | None/Unknown | 37,102 (91.55) | 708 (88.39) | 0.0019 |
| Yes | 3,425 (8.45) | 93 (11.61) | ||
| Systemic (%) | None/Unknown | 38,183 (94.22) | 743 (92.76) | 0.0951 |
| Yes | 2,344 (5.78) | 58 (7.24) |